PDE4A and chronic obstructive pulmonary disease: Over the past decades, significant progress in medicinalchemistryhas led to the development of highly potent PDE4 inhibitors, suchas Cilomilast and Roflumilast, which have undergone clinical trialsfor asthma and chronic obstructive pulmonary disease (COPD).